TCR2 Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$173.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.(i)
  • TCR2 Therapeutics received $125.0M in venture funding in March 2018.
  • TCR2 Therapeutics's estimated revenue per employee is $24,429
  • TCR2 Therapeutics's total funding is $173.3M.
  • TCR2 Therapeutics's current valuation is $153.3M. (January 2022)

Employee Data

  • TCR2 Therapeutics has 184 Employees.(i)
  • TCR2 Therapeutics grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.

keywords:Biotechnology,Healthcare

$173.3M

Total Funding

184

Number of Employees

$4.5M

Revenue (est)

5%

Employee Growth %

$153.3M

Valuation

N/A

Accelerator

TCR2 Therapeutics News

2022-04-17 - Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ ...

Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Announce Earnings of -$0.74 Per Share. Posted by admin on Apr 20th, 2022.

2022-03-30 - TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Benzinga

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from...

2022-03-30 - TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC ...

TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...

2019-09-12 - TCR2 Therapeutics, NCI Team Up to Test TC-210 ...

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...

2019-08-31 - TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?

TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$44.5M1841%N/A
#2
$35M184N/AN/A
#3
$28.7M18558%N/A
#4
$15M185N/AN/A
#5
$21M1875%N/A

TCR2 Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-12-12$44.5MAMPM CapitalArticle
2018-03-22$125.0MB6 Dimensions CapitalArticle